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ABSTRACT 
Animal models are fundamental basis for understanding the mechanism of neuropathic pain and development of novel treatments for best possible 
management of the disease. Neuropathic pain models are developed for manifestation of clinical pain conditions. This review meticulously examines 
the technique, behavioural modifications, limitations, and advantages of most recurrently used animal models of neuropathic pain. Animal models 
have vastly contributed in understanding the mechanisms of this debilitating disease. Moreover, these models have also resulted in development of 
novel therapeutic agents and better management of the neuropathic pain. This article comprehensively reviews some of the most frequently used 
models of neuropathic pain. 
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INTRODUCTION 
The International Association for the Study of Pain (IASP) defines 
neuropathic pain as "pains resulting from disease or damage of the 
peripheral or central nervous systems, and from dysfunction of the 
nervous system [1]. Neuropathic pain could be a blend of many 
sensory indications such as paresthesias (numbness or tingling), 
dysesthesias (electric shock phenomenon), hyperesthesia (increased 
sensitivity to mild painful stimuli), hyperalgesia (increased 
sensitivity to normally painful stimuli), hyperpathia (pain produced 
by subthreshold stimuli), spontaneous pain and allodynia (pain 
produced by normally non painful stimuli [2]. Pain in animals can 
only be judged by examining their responses to various chemical, 
thermal, and mechanical stimuli, with the latency or nature of 
response changed in the status of pain as compared to control group 
[3]. Animal models have been used widely in pain research as these 
models are capable to serve as substitute assay that can dependably 
evaluate the potency and efficacy of the pharmacological 
intervention [4]. Mechanisms causing neuropathic pain have been 
studied comprehensively in recent times because there has been 
enormous advancement in availability of clinically significant animal 
models to study these painful conditions. Most of the neuropathic 
pain models are made by causing diseases or injuries to the spinal 
cord or peripheral nerves. This review expresses some of the most 
frequently used models though many other models have also been 
reported [5-9]. The behavioral testing methods for acute pain can 
also be useful for evaluating chronic pain. The various behavioral 
tests include gait (limping), nocifensive signs (excessive grooming, 
paw licking, guarding, exploratory behavior and biting) [10-12], 
allodynia (Tactile allodynia and Cold allodynia) [13-15], thermal 
hyperalgesia (Radiant heat test and Hot-plate) [16] and mechanical 
hyperalgesia [17]. 
Central Pain Models 
Neuropathic pain is an example of chronic pain with SCI [18], and at 
least 30 percent of patients develop reasonable central pain. 
Neuropathic pain results from the abnormal processing of sensory 
input due to injury to the CNS. Nociceptive pain related with SCI is 
either musculoskeletal or visceral and located in those associated 
structures and generally eases with rest. In animal models of central 
pain that depend on induced nociception after SCI, allodynia and 
hyperalgesia are dependent on direct observation and measurement 
of nocifensive behaviors, which include withdrawal of a stimulated 
limb or tail. However, in humans there could be difference between 
reported chronic pain and elicited nociception.  
The commonly used models for central pain include spinal cord 
compression [19, 20]. Nocifensive signs crushing of spinal cord with 
forceps or aneurysm [21], photochemically induced injury, 
excitatory neurotoxin methods, and spinal hemisection [22]. 
Weight-drop or contusion model 
This is an oldest and most widely used model for central pain. It 
works by causing damage to spinal cord. Dorsal surface of the spine 
is exposed surgically and then weight is dropped on it causing spinal 
cord injury (SCI). It causes complete segmental necrosis. 
Modifications of this model also exist and give better results [23]. 
Excitotoxic spinal cord injury (ESCI) 
Considerable neurochemical changes take place post spinal cord injury 
(SCI). Intraspinal injection of neurochemicals such as serotonin, 
tryptamine, N methyl D aspartate and glutamate is known to produce 
symptoms similar to that of spinal cord injury. Many other 
neurochemicals have also been used to mimic SCI pain [24, 25]. 
Photochemical SCI model 
This model makes use of photosensitizing dye erythrosin B. 
Erythrosin B is intravenously injected and excited by argon laser at 
the exposed location where it produces vessel occlusion leading to 
ischemia and consequently leads to parenchymal tissue damage of 
spinal cord. Self mutilation, hyperalgesia, mechanical and cold 
allodynia can be easily observed [26].  
Peripheral nerve injury models 
Numerous pain models have been developed that employ injury to a 
peripheral nerve for instance sciatic nerve which produces short-
term or everlasting behavioural hypersensitivity and animal 
becomes susceptible to various behavioural tests such as tactile 
allodynia or thermal hyperalgesia. This hypersensitivity develops 
over several days after the peripheral nerve injury and may lead to 
chronic pain [27]. Allodynia is the unusual response with change in 
threshold level, to a non noxious stimulus, such as tactile 
stimulation. Hyperalgesia is a decrease in the latency of response to 
normally noxious stimuli, such as radiant heat [28]. Depending on 
the tightness of nerve ligation, the allodynia and hyperalgesia may 
alleviate in about 8 weeks or it may persist for several months. Partial 
nerve injuries include unilateral loose ligation or chronic constriction 
injury (CCI) of the sciatic nerve. Due to this the animal may persistently 
hold the ipsilateral hind paw in a guarded position [29]. 
Chronic constriction injury model (CCI or Bennett model) 
In this model sciatic nerve of right or left side is loosely ligated at 
four places at the mid thigh level. Rats with CCI display excessive 
licking, limping of ipsilateral hind paw, guarding, self-mutilation and 
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attack denervated area. Hyperalgesia due to noxious thermal and 
mechanical stimuli is detectable, alongwith cold allodynia and tactile 
allodynia. All pain symptoms persist approximately for two months [29]. 
Partial sciatic nerve ligation model (PSL or Seltzer model) 
This model rat model for inducing neuropathic pain was suggested 
by Seltzer and co- workers in 1990. The technique requires ligation 
of the ipsilateral sciatic nerve at upper thigh level, so that 1/3–1/2 
width of the sciatic nerve is trapped in ligature. After PSL rats 
display allodynia, guarding, licking, spontaneous pain, hyperalgesia 
to both thermal and mechanical within few hours of ligation. All the 
signs and symptoms last for over seven months [30]. 
L5 /L6 spinal nerve ligation model (SNL) 
In the SNL, L5 and L6 spinal nerves are unilaterally and tightly 
ligated at a location distal to the dorsal root ganglia. Hyperalgesia 
and allodynia develop soon after ligation. The symptoms last 
approximately for four months. Behavioural signs such as licking, 
lifting of ipsilateral hind paw, guarding are present. Autotomy is not 
present in this model [31]. 
Sciatic cryoneurolysis model (SCN) 
This model implies freezing of sciatic nerve. Touch allodynia and 
autotomy are present after SCN. Cryoneurolysis-induced nerve 
injury is sometimes reversible in nature so healing process od 
disease can be studied in this model. Touch allodynia, autotomy and 
spontaneous nociceptive behaviours last for shorter duration (15-21 
days) as compared to above mentioned models [32, 33]. 
L5 spinal nerve ligation 
This model has not been completely characterised yet. It is easier to 
execute than L5/L6 ligation and rats show prolonged signs of 
hyperalgesia and mechanical allodynia. It is a better model for 
studies involving mice. Chung model may mean L5/L6 spinal nerve 
ligation or only L5 ligation [34]. 
Axotomy model (complete sciatic nerve transection; neuroma 
model) 
This is one of the oldest models for inducing neuropathic pain. It 
employs transection of entire sciatic nerve at mid-thigh level [35]. 
The exposed sciatic nerve is freed from the connective tissue and 
then it is tightly ligated by nylon suture, proximal to the junction of 
tibial and peroneal divisions at two locations with about 1-cm gap. 
The nerve is then completely transected among the pair of ligatures, 
and 5 mm of the nerve between the ligatures is removed to check the 
re-joining of nerves due to regeneration. Following complete nerve 
transection, a neuroma develops at the proximal nerve end 
consisting of regenerative nerves emerging in all directions [36]. 
Caudal trunk resection 
In this model the left inferior caudal trunk is resected between the 
S3 and S4 spinal nerves due to which there is development of 
mechanical, cold, and warm allodynia in the tail which persists for 
several weeks. The symptoms of mechanical and thermal allodynia 
appear in a day after the nerve injury [37]. 
Spared nerve injury (SNI) 
This is a latest animal model of neuropathic pain developed by 
Decosterd and Woolf [38]. In this model, rats are anesthetized. The 
skin on the lateral surface of the left thigh is shaved and a dissection 
is made straight through the biceps femoris muscle. The sciatic 
nerve and its three terminal branches namely sural, common 
peroneal, and tibial are exposed. After that, the tibial and the 
common peroneal nerves are tightly ligated followed by axotomy of 
2 mm of distal nerve. An enormous care is taken to avoid any contact 
with the sural nerve. Since sural nerve remains totally untouched so 
this model is referred as ‘Spared Nerve Injury (SNI) model’. Two 
other modifications of SNI injury of the sciatic nerve have also been 
developed by similar surgical procedure, but by using different 
combinations of nerve transections. The mechanical and thermal 
hyperalgesia and allodynia occur within four days of SNI, which 
continues for several months post injury [38, 39]. 
Neuropathic pain due to medical conditions 
In human beings certain ailments such as diabetes, shingles and 
cancer are responsible for causing neuropathic affliction. Diabetes 
mellitus is the leading cause of neuropathy in the Western world 
[40]. In one series of studies, neuropathy is present in 66% of 
diabetic patients [34]. Shingles is associated with painful rashes. 
Shingles is also associated with painful postherpatic neuralgia which 
may persist throughout life. [41] 
Diabetic neuropathic pain model (DNP) 
Neuropathy occurs for both type 1 diabetes mellitus (T1DM) and 
type 2 diabetes mellitus (T2DM), suggesting that hyperglycaemia is 
the primary etiologic factor [42] A few diabetic models are available, 
e.g. insulin deficient BB rats [43] and NOD (non obese diabetic mice). 
[44] Most frequently used chemical methods to induce diabetic 
neuropathic pain are by streptozotocin. The behavioural signs 
observed in STZ-treated animals are allodynia and thermal 
sensitivity probably due to the sensitization of cutaneous 
nociceptors associated with Aδ and C fibers [45, 46]. 
Postherpetic neuralgia model (PHN) 
Varicella zoster virus (VZV) is an extremely virulent neurotropic 
virus and it is responsible for causing varicella (chickenpox) as the 
primary infection and at advance stage the virus transports 
retrospectively down the axons of sensory neurons from the skin to 
set up a latent infection within sensory ganglia of the peripheral 
nervous system [47]. Postherpatic neuralgia (PHN) is characterized 
by the presence of both spontaneous and evoked pain symptoms. A 
recent study concluded persistent allodynia and hyperalgesia in a rat 
model of latent varicella zoster infection [48]. 
Drug induced neuropathic pain 
Vincristine induced neuropathic pain  
The alkaloid vincristine is an antineoplastic drug which causes 
neuropathy. Vincristine has been used widely as chemotherapeutic 
agents for the treatment of several malignancies including breast 
cancer, leukaemia, lymphomas, and primary brain tumours [49]. 
However, clinical use of vincristine has been associated with the 
development of neurotoxicity of peripheral nerve fibres. Painful 
paresthesia is generally the very first sign in most of the patients. 
Vincristine is known to cause dose dependent neuropathy [50]. 
Cisplatin induced neuropathic pain 
Cisplatin has established its efficacy against many different types of 
malignancies such as ovarian, head, neck, testicular, colon and lung 
cancers. Emesis, anorexia, nephrotoxicity, myelo-suppression, 
ototoxicity and peripheral neuropathy is frequently coupled with its 
use [51]. 
Paclitaxel-induced neuropathy 
Paclitaxel derived from Taxus brevifolia. It is potent anti-cancer drug 
and is usually incorporated in chemotherapy for the treatment of 
breast, ovarian, head and neck cancers. Paclitaxel is known to cause 
sensory neuropathies which are generally categorized by tingling, 
numbness, mechanical allodynia, cold allodynia, and spontaneously 
evoked burning pain in distal extremities [51, 52]. 
Docetaxel-induced peripheral neuropathy 
It is a semisynthetic taxane, which is broadly used to treat various 
malignancies such as breast, ovarian and non-small cell lung cancers 
[53]. Its efficiency is restricted due to throbbing pain in peripheral 
neuropathies. It produces neuropathy in dose dependent manner 
[54]. In Docetaxel-induced neuropathic pain model i.v. injection of 
docetaxel (5; 10 or 12.5 mg/kg) for 4 weeks is given to induce 
neuropathy in rats. Docetaxel-treated rats demonstrate decreased 
tail nerve conduction velocity, changes in thermal threshold, and 
degeneration of foot pad skin nerves [55, 56]. 
Anti-HIV drugs-induced neuropathy 
Highly active anti-retroviral therapy (HAART) is the most efficient 
therapy for AIDS and encompasses various nucleoside reverse 
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transcriptase inhibitors (NRTIs) such as zalcitabine, didanosine and 
stavudine as its components. These drugs have a prominent side 
effect to produce painful neuropathies and to enhance pain 
perception caused by HIV-1 infection. [57,58] Some NRTIs are more 
prominent to cause neuropathy than others such as zalcitabine 
which is more potent than didanosine, which is further more potent 
than stavudine especially for causing sensory neurotoxicity. The 
other NRTIs namely zidovudine and abacavir are not known to cause 
any neuropathy [57]. Anderson et al. [59] established the neurotoxic 
effect of zalcitabine in rabbits, and Schmued et al. illustrated the 
effect of didanosine in brain and nerves of rats [60]. 
CONCLUSION 
Neuropathic pain has varied etiology which is difficult to 
understand. The development of animal models has significantly 
enhanced our understanding about pain and various mechanisms 
contributing to it. Peripheral nerve injury models such as PSL, 
SCL,CCI and neuroma models are more frequently used for 
mimicking peripheral pain whereas; spinal cord injury models are a 
superior alternative for understanding of mechanisms leading to 
central pain. Though rat models can also be employed in mice but 
different species elicit different response to similar injury or disease. 
Additionally pain models due to chemotherapeutic agents, diabetes, 
HIV have contributed to better understanding of their 
pathophysiology and management.  
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